Egalet Corporation , a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced that it has partnered with OraPharma, Inc., a division of Valeant Pharmaceuticals International, Inc., to co-promote Sprix (ketorolac tromethamine) nasal spray to dentists, dental specialists and oral surgeons across the United States.
Sprix nasal spray is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the short-term (up to five days in adults) management of moderate to moderately severe pain that requires analgesia at the opioid level.
"Given the need for additional non-narcotic analgesics in the dental space, we believe Sprix nasal spray offers an attractive product profile that can complement the OraPharma line of oral health products," said Mark Strobeck, Ph.D., chief operating officer. "This partnership, which expands our commercial reach, represents one aspect of our business development strategy which also includes acquisition of late-stage or approved assets and out-licensing of our Guardian Technology pipeline product candidates."
OraPharma will begin promoting Sprix in the first quarter as part of a two-year agreement. Financial terms of the agreement will not be disclosed. Egalet has terminated its agreement with Septodont. Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has three approved products: Arymo ER (morphine sulfate) extended-release tablets for oral use —CII, developed using Egalet's proprietary Guardian Technology, Oxaydo (oxycodone HCI, USP) tablets for oral use only —CII and Sprix (ketorolac tromethamine) Nasal Spray. Using Guardian Technology, Egalet is developing a pipeline of clinical-stage, product candidates for which we are seeking partners including Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles.